Anti-CTLA-4 therapy requires an Fc domain for efficacy

Jessica R. Ingram, Olga S. Blomberg, Mohammad Rashidian, Lestat Ali, Scott Garforth, Elena Fedorov, Alexander A. Fedorov, Jeffrey B. Bonanno, Camille Le Gall, Stephanie Crowley, Camilo Espinosa, Tamara Biary, Edmund J. Keliher, Ralph Weissleder, Steven C. Almo, Stephanie K. Dougan, Hidde L. Ploegh, Michael Dougan

Research output: Contribution to journalArticle

33 Scopus citations

Abstract

Ipilimumab, a monoclonal antibody that recognizes cytotoxic T lymphocyte antigen (CTLA)-4, was the first approved “checkpoint”-blocking anticancer therapy. In mouse tumor models, the response to antibodies against CTLA-4 depends entirely on expression of the Fcγ receptor (FcγR), which may facilitate antibody-dependent cellular phagocytosis, but the contribution of simple CTLA-4 blockade remains unknown. To understand the role of CTLA-4 blockade in the complete absence of Fc-dependent functions, we developed H11, a high-affinity alpaca heavy chain-only antibody fragment (VHH) against CTLA-4. The VHH H11 lacks an Fc portion, binds monovalently to CTLA-4, and inhibits interactions between CTLA-4 and its ligand by occluding the ligand-binding motif on CTLA-4 as shown crystallographically. We used H11 to visualize CTLA-4 expression in vivo using whole-animal immuno-PET, finding that surface-accessible CTLA-4 is largely confined to the tumor microenvironment. Despite this, H11-mediated CTLA-4 blockade has minimal effects on antitumor responses. Installation of the murine IgG2a constant region on H11 dramatically enhances its antitumor response. Coadministration of the monovalent H11 VHH blocks the efficacy of a full-sized therapeutic antibody. We were thus able to demonstrate that CTLA-4-binding antibodies require an Fc domain for antitumor effect.

Original languageEnglish (US)
Pages (from-to)3912-3917
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume115
Issue number15
DOIs
StatePublished - 2018

Keywords

  • CTLA-4
  • Cancer
  • Checkpoint blockade
  • Immunotherapy
  • Single-domain antibody

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Anti-CTLA-4 therapy requires an Fc domain for efficacy'. Together they form a unique fingerprint.

  • Cite this

    Ingram, J. R., Blomberg, O. S., Rashidian, M., Ali, L., Garforth, S., Fedorov, E., Fedorov, A. A., Bonanno, J. B., Le Gall, C., Crowley, S., Espinosa, C., Biary, T., Keliher, E. J., Weissleder, R., Almo, S. C., Dougan, S. K., Ploegh, H. L., & Dougan, M. (2018). Anti-CTLA-4 therapy requires an Fc domain for efficacy. Proceedings of the National Academy of Sciences of the United States of America, 115(15), 3912-3917. https://doi.org/10.1073/pnas.1801524115